Naloxegol Oxalate Interactions

7 DRUG INTERACTIONS Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) : Increased naloxegol concentrations; avoid concomitant use; if unavoidable, reduce dosage to 12.5 mg once daily and monitor for adverse reactions. Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) Avoid use with moderate CYP3A4 inhibitors; if unavoidable, decrease the dosage of MOVANTIK to 12.5 mg once daily and monitor for adverse reactions [see Dosage and Administration (2.4) ] .

Source: FDA drug label - naloxegol oxalate

Effects of Other Drugs on MOVANTIK Concomitant Agent Mechanism of Action Clinical Recommendation CYP3A4 Inhibitors Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) Increase plasma naloxegol concentrations and may increase the risk of adverse reactions [see Clinical Pharmacology (12.3) ].

Source: FDA drug label - naloxegol oxalate

Effects of Other Drugs on MOVANTIK Concomitant Agent Mechanism of Action Clinical Recommendation CYP3A4 Inhibitors Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) Increase plasma naloxegol concentrations and may increase the risk of adverse reactions [see Clinical Pharmacology (12.3) ].

Source: FDA drug label - naloxegol oxalate

Effects of Other Drugs on MOVANTIK Concomitant Agent Mechanism of Action Clinical Recommendation CYP3A4 Inhibitors Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) Increase plasma naloxegol concentrations and may increase the risk of adverse reactions [see Clinical Pharmacology (12.3) ].

Source: FDA drug label - naloxegol oxalate